Other Events ·
Denali Therapeutics Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) on July 27…
DNLIDenali Therapeutics Inc.
Denali Therapeutics Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) on July 27, 2026, receiving gross proceeds of $195.0 million. The PRV was obtained in March 2026 following the U.S. FDA approval of AVLAYA (tividenofusp alfa) for the treatment of Hunter syndrome. The transaction was executed under an asset purchase agreement dated June 12, 2026. Denali Therapeutics Inc. operates in the biopharmaceutical industry, focusing on the development of treatments for rare and difficult-to-treat diseases.